Development of indole hybrids for potential lung cancer treatment - part II DOI
Shanshan Huang,

Zhi Xu,

Yafei Zhuang

и другие.

Future Medicinal Chemistry, Год журнала: 2025, Номер unknown, С. 1 - 17

Опубликована: Март 30, 2025

Lung cancer has become the most prevalent for past three decades, and 5-years survival rate of lung is only ~20% nowadays. Chemotherapy mainstay therapy, especially non-small cell cancer. However, drug resistance represents a principal cause therapeutic failure in leading to insensitivity, tumor recurrence, disease progression. Indole hybrids have potential conquer resistance, enhance efficacy, reduce adverse events, improve pharmacokinetic properties due their capacity inhibit multiple targets simultaneously. Moreover, indole osimertinib, mobocertinib, cediranib, vizimpro are currently applied clinics demonstrating that valuable scaffolds treatment eradication This review provides comprehensive overview evolving landscape with vitro vivo efficacy against cancer, structure–activity relationships as well mechanisms action also discussed, covering articles published from 2021 onward.

Язык: Английский

Development of indole hybrids for potential lung cancer treatment - part II DOI
Shanshan Huang,

Zhi Xu,

Yafei Zhuang

и другие.

Future Medicinal Chemistry, Год журнала: 2025, Номер unknown, С. 1 - 17

Опубликована: Март 30, 2025

Lung cancer has become the most prevalent for past three decades, and 5-years survival rate of lung is only ~20% nowadays. Chemotherapy mainstay therapy, especially non-small cell cancer. However, drug resistance represents a principal cause therapeutic failure in leading to insensitivity, tumor recurrence, disease progression. Indole hybrids have potential conquer resistance, enhance efficacy, reduce adverse events, improve pharmacokinetic properties due their capacity inhibit multiple targets simultaneously. Moreover, indole osimertinib, mobocertinib, cediranib, vizimpro are currently applied clinics demonstrating that valuable scaffolds treatment eradication This review provides comprehensive overview evolving landscape with vitro vivo efficacy against cancer, structure–activity relationships as well mechanisms action also discussed, covering articles published from 2021 onward.

Язык: Английский

Процитировано

0